Moderna Stock Surges as New Vaccines Launch Approaches
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 days ago
0mins
Source: Yahoo Finance
- Stock Performance: Moderna's stock surged 6.27% on Tuesday to close at $55.40, marking its fourth consecutive day of gains, reflecting investor optimism about the upcoming vaccine launches that could drive future revenue growth.
- Vaccine Launch Plans: The company announced plans to launch flu plus COVID, seasonal flu, and norovirus vaccines between 2027 and 2028, demonstrating its ongoing innovation in vaccine development, which may enhance its competitive position in the market.
- Clinical Milestones: Moderna expects significant clinical data readouts this year, including for its investigational individualized neoantigen therapy (Intismeran autogene) and a treatment for the rare genetic disorder propionic acidemia, which could support the launch of its first oncology and rare disease products, further expanding its product portfolio.
- Executive Appointment: Ester Banque has been appointed as the new Chief Commercial Officer, tasked with building the global commercial organization and expanding into new markets, with her extensive experience expected to drive further growth in the vaccine market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 61.800
Low
17.00
Averages
32.47
High
63.00
Current: 61.800
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna's Flu Vaccine Gains FDA Advisory Panel Support
- Vaccine Safety Assessment: The FDA advisory panel unanimously concluded that the benefits of Moderna's mRNA flu vaccine, mRNA-1010, outweigh the risks for individuals aged 50 to 75, indicating its potential value in the elderly population.
- Clinical Trial Data: The committee's decision was based on data from several studies, including a late-stage trial involving over 40,000 adults aged 50 and older (Study 304) and another targeting nearly 3,000 adults aged 65 and above (Study 303 Part C), providing robust support for the vaccine's efficacy.
- Approval Process Review: Despite facing a significant setback in February when the FDA issued a refusal-to-file letter citing a lack of “adequate and well-controlled” trials, the agency reversed its decision later that month, reflecting a renewed assessment of the vaccine's potential.
- Future Outlook: Moderna's Biologics License Application (BLA) is expected to reach an FDA action date of August 5, and if approved, it will lay the groundwork for the company's further expansion in the flu vaccine market.
See More
Moderna's mRNA Flu Vaccine Receives Key Support from Advisory Committee
- Vaccine Receives Unanimous Support: The Vaccines and Related Biological Products Advisory Committee voted 9-0 that the benefits of mRNA-1010 (mFLUSIVA) outweigh its risks for adults aged 50-64, highlighting its potential importance for seasonal flu prevention in older adults.
- FDA Review Progress: The FDA is considering the advisory committee's non-binding recommendations and is expected to make a decision on Moderna's Biologics License Application by August 5, which could significantly impact the company's future market performance.
- Positive Stock Reaction: Following the committee's vote, Moderna's (MRNA) shares rose about 3%, with a cumulative increase of over 28% this week, marking its best performance since March 2022, reflecting market optimism regarding vaccine approval.
- Future Product Strategy: Moderna announced organizational changes to prepare for multiple product launches expected in 2027 and 2028, with the CEO stating that these moves will strengthen execution and support the commercialization of the flu vaccine and flu-COVID combination vaccine.
See More
Moderna's Influenza Vaccine Receives FDA Advisory Support
- Clinical Trial Results: Moderna's mRNA-1010 influenza vaccine received a 9-0 vote of support from the FDA's Vaccines Advisory Committee, indicating that its benefits outweigh risks for adults aged 50-64 and those 65 and older, highlighting its potential market value among older demographics.
- Safety Assessment: The safety profile observed in the Phase 3 clinical trial was consistent with previous candidates, enhancing its credibility as a differentiated non-egg-based option for influenza prevention, which may attract more healthcare institutions focused on elderly health.
- Regulatory Review Progress: The FDA has accepted the Biologics License Application (BLA) for mRNA-1010, setting a PDUFA goal date of August 5, 2026, indicating a clearer timeline for market launch that could provide new revenue streams for Moderna.
- Global Expansion Plans: Moderna plans to submit regulatory applications in 2026 across multiple countries including the U.S., EU, Canada, and Australia, demonstrating its strategic intent to promote mRNA-1010 globally and further solidify its leadership in the mRNA medicine field.
See More
Moderna's Influenza Vaccine Receives FDA Advisory Support
- Vaccine Safety Evaluation: The FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 to affirm that the benefits of mRNA-1010 outweigh its risks for preventing influenza in adults aged 50-64 and those 65 and older, indicating its potential value in the elderly population.
- Clinical Data Support: Data from Moderna's Phase 3 clinical trials have been published in The New England Journal of Medicine, further confirming mRNA-1010's differentiated potential as a non-egg-based option for influenza prevention, potentially providing a new preventive choice for older adults.
- Regulatory Review Progress: Moderna's Biologics License Application (BLA) is under FDA review with a PDUFA goal date set for August 5, 2026, indicating an accelerated strategic positioning in the influenza vaccine market.
- Global Regulatory Plans: In addition to the U.S., mRNA-1010 is undergoing regulatory review in the European Union, Canada, and Australia, with plans for submissions in additional countries, demonstrating Moderna's intent to expand in global markets.
See More
Three Stocks Thriving Amid Economic Headwinds
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine, mRNA-1010, aimed at addressing the low effectiveness of current flu vaccines, particularly for the elderly, which could significantly enhance its competitive position in the vaccine market.
- Krystal Biotech Strong Performance: Krystal Biotech has achieved positive earnings for 11 consecutive quarters with its gene therapy Vyjuvek, and as it expands into new markets in Europe, its revenue is expected to continue growing, showcasing its strong potential in the biotech sector.
- AMD Market Share Growth: AMD's stock has surged 129% year-to-date, with its desktop CPU market share rising to 33.2% and achieving a record 46.2% revenue share, indicating its strong competitive edge and pricing power in the AI sector.
- AI Market Opportunities: With the rise of agentic AI systems, AMD's EPYC processors are positioned as leaders in the server CPU market, potentially benefiting from a $200 billion market opportunity, further solidifying its industry standing.
See More
Investment Outlook for Moderna, Krystal Biotech, and AMD
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine mRNA-1010, which addresses a critical need for effective vaccines among the elderly, potentially enhancing the company's market position and financial performance significantly.
- Krystal Biotech Growth Potential: Krystal Biotech has achieved 11 consecutive quarters of earnings growth with its gene therapy Vyjuvek for a rare disease, and it still has a large addressable market to explore, with upcoming clinical data likely to further boost its stock price.
- AMD Market Leadership: AMD's stock has soared 129% year-to-date, and its leadership in the server CPU market positions it well to capitalize on the rapidly growing artificial intelligence sector, which is expected to continue driving revenue and market share growth.
- Economic and Market Performance: Despite economic and geopolitical challenges, the S&P 500 has risen 8% so far this year, demonstrating overall market resilience, with standout performances from companies like Moderna, Krystal Biotech, and AMD, making them attractive investment options.
See More
Moderna's Flu Vaccine Gains FDA Advisory Panel Support
- Vaccine Safety Assessment: The FDA advisory panel unanimously concluded that the benefits of Moderna's mRNA flu vaccine, mRNA-1010, outweigh the risks for individuals aged 50 to 75, indicating its potential value in the elderly population.
- Clinical Trial Data: The committee's decision was based on data from several studies, including a late-stage trial involving over 40,000 adults aged 50 and older (Study 304) and another targeting nearly 3,000 adults aged 65 and above (Study 303 Part C), providing robust support for the vaccine's efficacy.
- Approval Process Review: Despite facing a significant setback in February when the FDA issued a refusal-to-file letter citing a lack of “adequate and well-controlled” trials, the agency reversed its decision later that month, reflecting a renewed assessment of the vaccine's potential.
- Future Outlook: Moderna's Biologics License Application (BLA) is expected to reach an FDA action date of August 5, and if approved, it will lay the groundwork for the company's further expansion in the flu vaccine market.
See More
Moderna's mRNA Flu Vaccine Receives Key Support from Advisory Committee
- Vaccine Receives Unanimous Support: The Vaccines and Related Biological Products Advisory Committee voted 9-0 that the benefits of mRNA-1010 (mFLUSIVA) outweigh its risks for adults aged 50-64, highlighting its potential importance for seasonal flu prevention in older adults.
- FDA Review Progress: The FDA is considering the advisory committee's non-binding recommendations and is expected to make a decision on Moderna's Biologics License Application by August 5, which could significantly impact the company's future market performance.
- Positive Stock Reaction: Following the committee's vote, Moderna's (MRNA) shares rose about 3%, with a cumulative increase of over 28% this week, marking its best performance since March 2022, reflecting market optimism regarding vaccine approval.
- Future Product Strategy: Moderna announced organizational changes to prepare for multiple product launches expected in 2027 and 2028, with the CEO stating that these moves will strengthen execution and support the commercialization of the flu vaccine and flu-COVID combination vaccine.
See More
Moderna's Influenza Vaccine Receives FDA Advisory Support
- Clinical Trial Results: Moderna's mRNA-1010 influenza vaccine received a 9-0 vote of support from the FDA's Vaccines Advisory Committee, indicating that its benefits outweigh risks for adults aged 50-64 and those 65 and older, highlighting its potential market value among older demographics.
- Safety Assessment: The safety profile observed in the Phase 3 clinical trial was consistent with previous candidates, enhancing its credibility as a differentiated non-egg-based option for influenza prevention, which may attract more healthcare institutions focused on elderly health.
- Regulatory Review Progress: The FDA has accepted the Biologics License Application (BLA) for mRNA-1010, setting a PDUFA goal date of August 5, 2026, indicating a clearer timeline for market launch that could provide new revenue streams for Moderna.
- Global Expansion Plans: Moderna plans to submit regulatory applications in 2026 across multiple countries including the U.S., EU, Canada, and Australia, demonstrating its strategic intent to promote mRNA-1010 globally and further solidify its leadership in the mRNA medicine field.
See More
Moderna's Influenza Vaccine Receives FDA Advisory Support
- Vaccine Safety Evaluation: The FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 to affirm that the benefits of mRNA-1010 outweigh its risks for preventing influenza in adults aged 50-64 and those 65 and older, indicating its potential value in the elderly population.
- Clinical Data Support: Data from Moderna's Phase 3 clinical trials have been published in The New England Journal of Medicine, further confirming mRNA-1010's differentiated potential as a non-egg-based option for influenza prevention, potentially providing a new preventive choice for older adults.
- Regulatory Review Progress: Moderna's Biologics License Application (BLA) is under FDA review with a PDUFA goal date set for August 5, 2026, indicating an accelerated strategic positioning in the influenza vaccine market.
- Global Regulatory Plans: In addition to the U.S., mRNA-1010 is undergoing regulatory review in the European Union, Canada, and Australia, with plans for submissions in additional countries, demonstrating Moderna's intent to expand in global markets.
See More
Three Stocks Thriving Amid Economic Headwinds
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine, mRNA-1010, aimed at addressing the low effectiveness of current flu vaccines, particularly for the elderly, which could significantly enhance its competitive position in the vaccine market.
- Krystal Biotech Strong Performance: Krystal Biotech has achieved positive earnings for 11 consecutive quarters with its gene therapy Vyjuvek, and as it expands into new markets in Europe, its revenue is expected to continue growing, showcasing its strong potential in the biotech sector.
- AMD Market Share Growth: AMD's stock has surged 129% year-to-date, with its desktop CPU market share rising to 33.2% and achieving a record 46.2% revenue share, indicating its strong competitive edge and pricing power in the AI sector.
- AI Market Opportunities: With the rise of agentic AI systems, AMD's EPYC processors are positioned as leaders in the server CPU market, potentially benefiting from a $200 billion market opportunity, further solidifying its industry standing.
See More
Investment Outlook for Moderna, Krystal Biotech, and AMD
- Moderna Vaccine Progress: Moderna is nearing approval for its influenza vaccine mRNA-1010, which addresses a critical need for effective vaccines among the elderly, potentially enhancing the company's market position and financial performance significantly.
- Krystal Biotech Growth Potential: Krystal Biotech has achieved 11 consecutive quarters of earnings growth with its gene therapy Vyjuvek for a rare disease, and it still has a large addressable market to explore, with upcoming clinical data likely to further boost its stock price.
- AMD Market Leadership: AMD's stock has soared 129% year-to-date, and its leadership in the server CPU market positions it well to capitalize on the rapidly growing artificial intelligence sector, which is expected to continue driving revenue and market share growth.
- Economic and Market Performance: Despite economic and geopolitical challenges, the S&P 500 has risen 8% so far this year, demonstrating overall market resilience, with standout performances from companies like Moderna, Krystal Biotech, and AMD, making them attractive investment options.
See More
